Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mingyi Chen

Showing results (171-180 of 216) with videos related to

Pageof 22
Sort By:
Science Immunology|February 23, 2020
Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomesTianshi Lu, Shidan Wang, Lin Xu, et al.
Cell Reports. Medicine|February 19, 2026
HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancerYong Wang, Yan Xiong, Shuiqiao Liu, et al.
Oncoimmunology|April 9, 2016
Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancerChristine Mall, Gail D Sckisel, David A Proia, et al.
Leukemia Research|December 2, 2022
Distinct mutational and clinicopathologic profiles characterize acute myeloid leukemia with cup-like nucleiEstelle Oertling, Franklin Fuda, Prasad Koduru, et al.
The American Journal of Case Reports|April 9, 2025
Imatinib-Induced Clinical Response in ETV6::ACSL6 Myeloid Neoplasm with Eosinophilic Pneumonitis: A Case ReportFieke W Hoff, Sharon Germans, Olga K Weinberg, et al.
Nanomedicine (London, England)|March 18, 2014
Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicinHongyong Zhang, Yuanpei Li, Tzu-Yin Lin, et al.
The Journal of Clinical Investigation|July 28, 2007
Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoEMichelle N Bradley, Cynthia Hong, Mingyi Chen, et al.
Science Immunology|August 11, 2019
Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunityZhida Liu, Chuanhui Han, Chunbo Dong, et al.
BMC Cancer|October 11, 2014
Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcomaRobert J Canter, Erik Ames, Stephanie Mac, et al.
Cell Reports. Medicine|January 21, 2026
Targeting severe acidity for tumor-activatable Interleukin-2 therapyQiang Feng, Raymundo Pantoja, Jacqueline G Lopez, et al.
Pageof 22

Showing results (171-180 of 216) with videos related to

Sort By:
Pageof 22
Science Immunology|February 23, 2020
Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomesTianshi Lu, Shidan Wang, Lin Xu, et al.
Cell Reports. Medicine|February 19, 2026
HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancerYong Wang, Yan Xiong, Shuiqiao Liu, et al.
Oncoimmunology|April 9, 2016
Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancerChristine Mall, Gail D Sckisel, David A Proia, et al.
Leukemia Research|December 2, 2022
Distinct mutational and clinicopathologic profiles characterize acute myeloid leukemia with cup-like nucleiEstelle Oertling, Franklin Fuda, Prasad Koduru, et al.
The American Journal of Case Reports|April 9, 2025
Imatinib-Induced Clinical Response in ETV6::ACSL6 Myeloid Neoplasm with Eosinophilic Pneumonitis: A Case ReportFieke W Hoff, Sharon Germans, Olga K Weinberg, et al.
Nanomedicine (London, England)|March 18, 2014
Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicinHongyong Zhang, Yuanpei Li, Tzu-Yin Lin, et al.
The Journal of Clinical Investigation|July 28, 2007
Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoEMichelle N Bradley, Cynthia Hong, Mingyi Chen, et al.
Science Immunology|August 11, 2019
Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunityZhida Liu, Chuanhui Han, Chunbo Dong, et al.
BMC Cancer|October 11, 2014
Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcomaRobert J Canter, Erik Ames, Stephanie Mac, et al.
Cell Reports. Medicine|January 21, 2026
Targeting severe acidity for tumor-activatable Interleukin-2 therapyQiang Feng, Raymundo Pantoja, Jacqueline G Lopez, et al.
Pageof 22